Exclusive Opportunity: Next-Generation Acne Serum

Exclusive Opportunity: Next-Generation Acne Serum

Team IPO is exclusively representing a scientifically advanced, microbiome-friendly acne serum currently progressing toward U.S. OTC readiness. We are seeking a strategic partner or acquirer with the scale, distribution power and dermatology expertise to bring this differentiated product to market.

The Opportunity

A novel topical serum designed to address typical acne lesions, including adult acne (acne tarda). Unlike conventional approaches that primarily suppress symptoms, this formulation targets a key microbial driver of acne while aiming to preserve the beneficial skin microbiome.

Key Differentiators

  • Microbiome-conscious mode of action
  • Root-cause oriented rather than purely symptomatic
  • Excellent tolerability profile (HRIPT supports “suitable for sensitive skin” claim)
  • Positive long-term stability data; successfully passed USP ⟨51⟩ pre-test
  • Brand name and hero-ingredient naming process well advanced
  • Clear path toward 2026 U.S. OTC launch readiness

Technology Platform (High-Level)

The product is based on a proprietary class of engineered antimicrobial proteins. These proteins are designed to act rapidly against relevant pathogenic bacteria, including within biofilms, while showing minimal collateral impact on beneficial flora. The platform is characterized by high potency, a favorable resistance profile by design, and environmental biodegradability.

Current Status

Formulation development is advanced. Stability, preservative efficacy and human repeat-insult patch testing results are available under confidentiality. The asset is positioned for a 2026 U.S. OTC pathway and is ready for partner due diligence.

Ideal Partner Profile

A company active in dermatology, consumer healthcare or medical aesthetics that is looking for a differentiated, science-backed acne product with strong IP potential and a clean regulatory route into the U.S. market.

Next Steps

Interested parties are invited to contact Team IPO. Full technical data, formulation details, intellectual property overview and commercial terms will be shared under NDA.

Contact

Team IPO GmbH
Schloss Hauptwil, Nordflügel
9213 Hauptwil, Switzerland

Please use the contact form on this website or reach out directly to discuss next steps under confidentiality.